BioventixLSE:BVXP 62 Net Margin % is 58.86% as of Dec. 2025, which is 8% below its 10-year median of 64.02. GuruFocus rates LSE:BVXP with a GF Score™ of 62/100 and a GF Value™ of £35.80 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 946 Biotechnology companies, Bioventix ranks better than 96.3% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Bioventix's Net Income for the
six
months ended in Dec. 2025 was £3.63 Mil. Bioventix's Revenue for the
six
months ended in Dec. 2025 was £6.16 Mil. Therefore, Bioventix's net margin for the quarter that ended in Dec. 2025 was 58.86%.
The historical rank and industry rank for Bioventix's Net Margin % or its related term are showing as below:
LSE:BVXP'
s Net Margin % Range Over the Past 10 Years
Min: 57.82 Med: 64.02 Max: 69.84
Current: 59.29
LSE:BVXP's Net Margin % is ranked better than 96.3% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs LSE:BVXP: 59.29
Bioventix (LSE:BVXP) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Bioventix Net Margin % Related Terms
Bioventix Net Margin % Historical Data
* Premium members only.
The historical data trend for Bioventix's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:BVXP vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Bioventix's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioventix Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bioventix's Net Margin % distribution charts can be found below:
* The bar in red indicates where Bioventix's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioventix (LSE:BVXP) has a Net Margin % of 58.86% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Bioventix and its competitors. This is near median its historical median of 64.02. Over the past decade, Bioventix's Net Margin % has ranged from 57.82 to 69.84. According to the industry distribution chart, Bioventix ranks #35 out of 946 companies in the Biotechnology industry, placing it in the top 3.7%.
Is Bioventix's Net Margin % too high?
Bioventix's current Net Margin % of 58.86% is near median its 10-year median of 64.02. Over the past 10 years, this metric has ranged from a low of 57.82 to a high of 69.84. Based on the distribution chart, Bioventix ranks #35 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bioventix has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioventix's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bioventix ranks #35 out of 946 companies for Net Margin %. This places Bioventix in the top 4% of its industry — outperforming the majority of peers. Historically, Bioventix's own Net Margin % has ranged from 57.82 to 69.84 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Bioventix and its competitors. Bioventix's current Net Margin % is 58.86%, which is near median its own 10-year median of 64.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioventix stock overvalued right now?
Based on GuruFocus' analysis, Bioventix (LSE:BVXP) is currently considered Significantly Undervalued. The stock's GF Value™ is £35.80, compared to a current price of £16.75 — trading 53.2% below its estimated fair value. The current Net Margin % is 58.86%, which is near median its 10-year median of 64.02. Bioventix's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Bioventix (LSE:BVXP), the current Net Margin % is 58.86% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioventix (LSE:BVXP) Overvalued in 2026?
Based on GuruFocus' analysis, Bioventix stock appears to be undervalued.
The current stock price of £16.75 is trading 53.2% below its estimated GF Value™ of £35.80.
GuruFocus considers Bioventix to be Significantly Undervalued.
Key valuation signals for LSE:BVXP:
Net Margin %: 58.86% (near median its 10-year median of 64.02)
GF Value™: £35.80 vs. price of £16.75 (53.2% below fair value)
No single metric tells the full story. See the LSE:BVXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
62GF Score
Get the complete analysis for LSE:BVXP
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BVXP has been successfully added to your 
